(Q31098999)

English

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

0 references

Coagulation factor VIII

0 references

0 references

0 references

0 references

author name string

H Pollmann

1

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

D Externest

2

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

A Ganser

3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

B Eifrig

4

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

W Kreuz

5

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

H Lenk

6

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

I Pabinger

7

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

W Schramm

8

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

T F Schwarz

9

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

R Zimmermann

10

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

N Zavazava

11

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

J Oldenburg

12

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

R Klamroth

13

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

131-143

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Hemophilia A--from basic science to clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Haemophilias A and B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Choice of replacement therapy for hemophilia: recombinant products only?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Viral safety of B-domain deleted recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Inhibitors in congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Inhibitors: resolving diagnostic and therapeutic dilemmas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Inhibitors in haemophilia: pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Environmental and genetic factors influencing inhibitor development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

The epidemiology of inhibitors in haemophilia A: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

High-titer inhibitor development in hemophilia A: lack of product specificity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Clinical outcomes and resource utilization associated with haemophilia care in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Prophylaxis for severe hemophilia: experience from Europe and the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Home management of haemophilia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Cost-utility analysis in evaluating prophylaxis in haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Barriers to compliance with prophylaxis therapy in haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Functional assessment of arthropathy--an international perspective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Inhibitors in haemophilia: a primer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01416.X

21 January 2018

Identifiers

10.1111/J.1365-2516.2006.01416.X

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31098999&oldid=1545661654"